查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1617062

到 2030 年抗神经丝 L 抗体的全球市场预测：按产品类型、应用、最终用户和地区进行分析

Anti Neurofilament L Antibody Market Forecasts to 2030 - Global Analysis By Product Type (Monoclonal Antibodies, Polyclonal Antibodies and Other Product Types), Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2024 年全球抗神经丝 L 抗体市场规模为 3.188 亿美元，预计到 2030 年将达到 6.1258 亿美元，预测期内复合年增长率为 11.5%。

抗神经丝 L (NfL) 抗体是专门设计用于与神经丝轻链 (NfL) 结合的特殊蛋白质，神经丝轻炼是神经细胞中普遍存在的结构蛋白。 NfL是识别神经元损伤的重要生物标记物，可用于研究和诊断日益增多的阿兹海默症、多发性硬化症和肌萎缩侧索硬化症（ALS）等神经退化性疾病。这些抗体支持神经系统疾病的早期检测和监测，对于开发诊断分析、研究神经元完整性和推进治疗技术至关重要。

据帕金森氏症基金会称，截至 2022 年，美国约有 100 万人患有帕金森氏症 (PD)。

神经退化性疾病盛行率上升

对抗神经丝 L (NfL) 抗体的需求主要是由神经退化性疾病（如多发性硬化症、帕金森氏症和阿兹海默症）日益流行所驱动。 NfL 是识别神经元细胞损伤的重要生物标记物，可用于早期诊断和病情监测。随着全球人口老化和这些疾病盛行率的增加，越来越需要先进的诊断技术。此外，学术界和医疗保健专业人员对 NfL 生物标记重要性的广泛了解加速了其在临床和研究环境中的使用，支持了市场扩张。

缺乏标准化的检测法

缺乏标准化检测方法是抗神经丝 L (NfL) 抗体市场的主要挑战，这对市场成长产生负面影响。检测通讯协定的变异性会损害临床诊断和研究的可靠性和再现性。这削弱了研究人员、医生和监管机构的信心，并阻碍了更广泛的采用。此外，缺乏通用标准使得很难比较不同研究的资料，从而减缓了新治疗方法的开发和神经退化性疾病的研究。为了解决这个问题，相关人员必须共同努力製定规范，以确保准确性、统一性和更广泛的可用性。

生物标记研究进展

生物标记研究正在推动抗神经丝 L (NfL) 抗体市场的显着成长。自从 NfL 被确定为神经退化性疾病的重要生物标记以来，超灵敏免疫测量（例如 Simoa）等新技术已将检测能力提高到以前无法达到的水平。这些进展使得早期诊断多发性硬化症、阿兹海默症和 ALS 等疾病、追踪病程、评估治疗效果等变得更加容易。随着研究进展证明 NfL 在临床试验中的效用，製药公司现在正在投资生物标记研究。

假阳性和假阴性的可能性

儘管 NfL 是神经退化性疾病的一种有前途的生物标记物，但它也存在假阳性和假阴性结果的风险，这可能会显着影响临床决策。样品处理、储存条件和干扰物质的存在等因素可能会影响 NfL 测量的准确性。此外，个体 NfL 水平各不相同，因此很难建立明确的诊断阈值。优化检测通讯协定、使用高品质试剂并实施严格的品管措施对于最大限度地减少错误结果的风险至关重要。

COVID-19 的影响

抗神经丝 L (NfL) 抗体的销售受到 COVID-19 疫情的严重影响。由于 COVID-19 与神经发炎和神经退化等神经系统症状有关，因此人们越来越关注 NfL 作为确定神经损伤程度和追踪疾病进程的生物标记。因此，出于诊断和研究目的，对 NfL 抗体的需求不断增加。基于 NfL 的诊断测试的采用也可能受到以下事实的影响：大流行加速了远距医疗解决方案的开发。

单株抗体领域预计将成为预测期内最大的市场

单株抗体片段估计是最大的，因为它们的高特异性、敏感性和重现性使其成为检测和定量各种生物样本中 NfL 水平的理想选择。单株抗体可设计用于靶向 NfL 蛋白上的特定表位，从而实现精确且准确的测量。此外，单株抗体技术的进步促进了高灵敏度和特异性检测的发展，进一步推动了市场成长。

学术机构领域预计在预测期内复合年增长率最高

学术机构领域预计在预测期内复合年增长率最高。这些机构对神经退化性疾病进行广泛的研究，利用 NfL 作为有价值的生物标记来了解疾病机制并确定潜在的治疗标靶。用于研究目的的高品质 NfL 抗体的需求正在推动市场成长。此外，与製药和生物技术公司的学术合作正在加速基于 NfL 的创新诊断工具和治疗性介入的开发。

比最大的地区

由于人口迅速老化、神经系统疾病发病率上升以及医疗设施扩张，预计亚太地区将在预测期内占据最大的市场占有率。该地区庞大的人口和不断增长的医疗保健支出显着增加了对 NfL 检测等先进诊断设备的需求。政府支持医疗保健和医学研究的计划的增加也推动了市场扩张。随着该地区进一步开发市场，对 NfL 抗体的需求预计将会增加，使其成为国际公司的重要市场。

复合年增长率最高的地区：

由于其发达的医疗基础设施、不断增加的老年人口以及对医疗保健研究和开发的重视，预计北美在预测期内的复合年增长率最高。该地区 ALS 和老年痴呆症神经退化性疾病的发生率不断增加，增加了对 NfL 等精确、敏感生物标记的需求。此外，北美着名製药和生物技术公司的存在也促进了基于 NfL 的诊断测试和治疗性介入的开发和行销。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争标基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球抗神经丝 L 抗体市场：依产品类型

  • 单株抗体
  • 多株抗体
  • 其他产品类型

第六章全球抗神经丝 L 抗体市场：依应用分类

  • 研究
  • 诊断
  • 药物发现与开发
  • 治疗药物
  • 其他用途

第七章全球抗神经丝 L 抗体市场：依最终用户分类

  • 学术机构
  • 製药和生物技术公司
  • 研究所
  • 其他最终用户

第八章全球抗神经丝L抗体市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第 10 章 公司概况

  • Merck KGaA
  • Abcam plc
  • Thermo Fisher Scientific Inc.
  • Santa Cruz Biotechnology, Inc.
  • Proteintech Group, Inc.
  • R&D Systems, Inc.
  • Boster Biological Technology
  • Rockland Immunochemicals Inc.
  • Bio-Rad Laboratories, Inc.
  • Cell Signaling Technology, Inc.
  • GeneTex, Inc.
  • Novus Biologicals, LLC
  • ProSci Inc.
  • Atlas Antibodies AB
  • LifeSpan BioSciences, Inc.
  • Creative Biolabs
  • BioLegend, Inc.
  • Abnova Corporation
  • PeproTech, Inc.
  • US Biological Life Sciences
Product Code: SMRC27939

According to Stratistics MRC, the Global Anti Neurofilament L Antibody Market is accounted for $318.80 million in 2024 and is expected to reach $612.58 million by 2030 growing at a CAGR of 11.5% during the forecast period. Anti-neurofilament L (NfL) antibodies are specialized proteins made to attach to the neurofilament light chain (NfL), a structural protein that is widely present in neurons. Research and diagnosis of neurodegenerative illnesses like Alzheimer's, multiple sclerosis, and amyotrophic lateral sclerosis (ALS) are increasingly using NfL, a critical biomarker for identifying neuronal damage. These antibodies support early detection and monitoring of neurological diseases and are essential for the development of diagnostic assays, research into neuronal integrity, and advancement of therapeutic techniques.

According to Parkinson's Foundation, as of 2022, nearly one million people in the United States are living with Parkinson's disease (PD).

Market Dynamics:

Driver:

Rising prevalence of neurodegenerative diseases

The need for anti-neurofilament L (NfL) antibodies is mostly driven by the increasing incidence of neurodegenerative illnesses such as multiple sclerosis, Parkinson's, and Alzheimer's. NfL is an essential biomarker for identifying neuronal injury, which helps with early diagnosis and status monitoring. Advanced diagnosis technologies are becoming more and more necessary as populations age and the prevalence of these ailments rises worldwide. Furthermore, increased knowledge of the significance of NfL biomarkers among academics and healthcare professionals has accelerated their use in clinical and research settings, supporting the market's expansion.

Restraint:

Lack of standardized assay methods

The lack of standardized assay methods in the Anti-Neurofilament L (NfL) Antibody Market poses significant challenges, negatively impacting its growth. Assay protocol variability produces variable results, which compromises clinical diagnostics and research study reliability and reproducibility. This hinders wider adoption by undermining trust among academics, physicians, and regulatory agencies. Furthermore, the lack of common standards makes it more difficult to compare data from different studies, which slows down the development of new treatments and research on neurodegenerative diseases. In order to resolve this issue, stakeholders must work together to create norms that guarantee accuracy, uniformity, and wider accessibility.

Opportunity:

Advancements in biomarker research

Research on biomarkers is propelling the market for anti-neurofilament L (NfL) antibodies to rise significantly. Novel technologies such as ultrasensitive immunoassays (e.g., Simoa) have improved detection capabilities at previously unachievable levels since NfL was identified as a crucial biomarker for neurodegenerative disorders. These developments facilitate early diagnosis, tracking the course of the disease, and assessing the effectiveness of treatment, especially for diseases like multiple sclerosis, Alzheimer's, and ALS. Pharmaceutical corporations are now investing in biomarker studies as a result of research advances that have demonstrated the usefulness of NfL in clinical trials.

Threat:

Potential for false positive and negative results

While NfL is a promising biomarker for neurodegenerative diseases, there is a risk of false positive and negative results, which can significantly impact clinical decision-making. Factors such as sample handling, storage conditions, and the presence of interfering substances can influence the accuracy of NfL measurements. Additionally, variations in individual NfL levels can make it challenging to establish definitive diagnostic thresholds. To minimize the risk of false results, it is essential to optimize assay protocols, use high-quality reagents, and implement rigorous quality control measures.

Covid-19 Impact

Anti-Neurofilament L (NfL) antibody sales have been greatly influenced by the COVID-19 epidemic. Since COVID-19 has been linked to neurological symptoms like neuroinflammation and neurodegeneration, there has been more interest in NfL as a possible biomarker for determining the extent of neurological damage and tracking the course of the illness. As a result, there is now more demand for NfL antibodies for both diagnostic and research applications. The adoption of NfL-based diagnostic tests may also be influenced by the pandemic's acceleration of the development of remote healthcare solutions.

The monoclonal antibodies segment is expected to be the largest during the forecast period

The monoclonal antibodies segment is estimated to be the largest, due to their high specificity, sensitivity, and reproducibility make them ideal for detecting and quantifying NfL levels in various biological samples. Monoclonal antibodies can be engineered to target specific epitopes on the NfL protein, enabling precise and accurate measurements. Additionally, advances in monoclonal antibody technology have led to the development of highly sensitive and specific assays, further driving the growth of the market.

The academic institutions segment is expected to have the highest CAGR during the forecast period

The academic institutions segment is anticipated to witness the highest CAGR during the forecast period. These institutions conduct extensive research on neurodegenerative diseases, utilizing NfL as a valuable biomarker to understand disease mechanisms and identify potential therapeutic targets. The demand for high-quality NfL antibodies for research purposes fuels the market's growth. Additionally, academic collaborations with pharmaceutical companies and biotechnology firms accelerate the development of innovative NfL-based diagnostic tools and therapeutic interventions.

Region with largest share:

Asia Pacific is expected to have the largest market share during the forecast period due to rapidly aging population, rising neurological disease rates, and expanding medical facilities. The need for sophisticated diagnostic instruments like NfL tests has increased significantly because to the region's high population and growing healthcare expenditures. The market's expansion is also being driven by an increase in government programs to support healthcare and medical research. The demand for NfL antibodies is anticipated to increase as the region develops further, making it a crucial market for international companies.

Region with highest CAGR:

North America is projected to witness the highest CAGR over the forecast period, because of a developed healthcare infrastructure, a growing senior population, and a strong emphasis on healthcare research and development. The increasing incidence of neurodegenerative illnesses like ALS and Alzheimer's in the area has raised the need for precise and sensitive biomarkers like NfL. Furthermore, the development and marketing of NfL-based diagnostic tests and therapeutic interventions have been expedited by the presence of prominent pharmaceutical and biotechnology firms in North America.

Key players in the market

Some of the key players profiled in the Anti Neurofilament L Antibody Market include Merck KGaA, Abcam plc, Thermo Fisher Scientific Inc., Santa Cruz Biotechnology, Inc., Proteintech Group, Inc., R&D Systems, Inc., Boster Biological Technology, Rockland Immunochemicals Inc., Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., GeneTex, Inc., Novus Biologicals, LLC, ProSci Inc., Atlas Antibodies AB, LifeSpan BioSciences, Inc., Creative Biolabs, BioLegend, Inc., Abnova Corporation, PeproTech, Inc., and US Biological Life Sciences.

Key Developments:

In October 2023, Quanterix Corporation launched a new high-sensitivity assay for measuring neurofilament light chain (NfL) levels, aimed at enhancing the early detection and monitoring of neurodegenerative diseases.

In September 2023, BioLegend introduced a new anti-neurofilament L antibody aimed at research applications, providing enhanced specificity and sensitivity for studying neurodegeneration.

In April 2023, Merck KGaA released an updated version of their anti-neurofilament L antibody, which includes improved formulations for better performance in clinical diagnostics.

Product Types Covered:

  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Other Product Types

Applications Covered:

  • Research
  • Diagnostics
  • Drug Discovery and Development
  • Therapeutics
  • Other Applications

End Users Covered:

  • Academic Institutions
  • Pharmaceutical and Biotechnology Companies
  • Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Anti Neurofilament L Antibody Market, By Product Type

  • 5.1 Introduction
  • 5.2 Monoclonal Antibodies
  • 5.3 Polyclonal Antibodies
  • 5.4 Other Product Types

6 Global Anti Neurofilament L Antibody Market, By Application

  • 6.1 Introduction
  • 6.2 Research
  • 6.3 Diagnostics
  • 6.4 Drug Discovery and Development
  • 6.5 Therapeutics
  • 6.6 Other Applications

7 Global Anti Neurofilament L Antibody Market, By End User

  • 7.1 Introduction
  • 7.2 Academic Institutions
  • 7.3 Pharmaceutical and Biotechnology Companies
  • 7.4 Laboratories
  • 7.5 Other End Users

8 Global Anti Neurofilament L Antibody Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Merck KGaA
  • 10.2 Abcam plc
  • 10.3 Thermo Fisher Scientific Inc.
  • 10.4 Santa Cruz Biotechnology, Inc.
  • 10.5 Proteintech Group, Inc.
  • 10.6 R&D Systems, Inc.
  • 10.7 Boster Biological Technology
  • 10.8 Rockland Immunochemicals Inc.
  • 10.9 Bio-Rad Laboratories, Inc.
  • 10.10 Cell Signaling Technology, Inc.
  • 10.11 GeneTex, Inc.
  • 10.12 Novus Biologicals, LLC
  • 10.13 ProSci Inc.
  • 10.14 Atlas Antibodies AB
  • 10.15 LifeSpan BioSciences, Inc.
  • 10.16 Creative Biolabs
  • 10.17 BioLegend, Inc.
  • 10.18 Abnova Corporation
  • 10.19 PeproTech, Inc.
  • 10.20 US Biological Life Sciences

List of Tables

  • Table 1 Global Anti Neurofilament L Antibody Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Anti Neurofilament L Antibody Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 3 Global Anti Neurofilament L Antibody Market Outlook, By Monoclonal Antibodies (2022-2030) ($MN)
  • Table 4 Global Anti Neurofilament L Antibody Market Outlook, By Polyclonal Antibodies (2022-2030) ($MN)
  • Table 5 Global Anti Neurofilament L Antibody Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 6 Global Anti Neurofilament L Antibody Market Outlook, By Application (2022-2030) ($MN)
  • Table 7 Global Anti Neurofilament L Antibody Market Outlook, By Research (2022-2030) ($MN)
  • Table 8 Global Anti Neurofilament L Antibody Market Outlook, By Diagnostics (2022-2030) ($MN)
  • Table 9 Global Anti Neurofilament L Antibody Market Outlook, By Drug Discovery and Development (2022-2030) ($MN)
  • Table 10 Global Anti Neurofilament L Antibody Market Outlook, By Therapeutics (2022-2030) ($MN)
  • Table 11 Global Anti Neurofilament L Antibody Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 12 Global Anti Neurofilament L Antibody Market Outlook, By End User (2022-2030) ($MN)
  • Table 13 Global Anti Neurofilament L Antibody Market Outlook, By Academic Institutions (2022-2030) ($MN)
  • Table 14 Global Anti Neurofilament L Antibody Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
  • Table 15 Global Anti Neurofilament L Antibody Market Outlook, By Laboratories (2022-2030) ($MN)
  • Table 16 Global Anti Neurofilament L Antibody Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 17 North America Anti Neurofilament L Antibody Market Outlook, By Country (2022-2030) ($MN)
  • Table 18 North America Anti Neurofilament L Antibody Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 19 North America Anti Neurofilament L Antibody Market Outlook, By Monoclonal Antibodies (2022-2030) ($MN)
  • Table 20 North America Anti Neurofilament L Antibody Market Outlook, By Polyclonal Antibodies (2022-2030) ($MN)
  • Table 21 North America Anti Neurofilament L Antibody Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 22 North America Anti Neurofilament L Antibody Market Outlook, By Application (2022-2030) ($MN)
  • Table 23 North America Anti Neurofilament L Antibody Market Outlook, By Research (2022-2030) ($MN)
  • Table 24 North America Anti Neurofilament L Antibody Market Outlook, By Diagnostics (2022-2030) ($MN)
  • Table 25 North America Anti Neurofilament L Antibody Market Outlook, By Drug Discovery and Development (2022-2030) ($MN)
  • Table 26 North America Anti Neurofilament L Antibody Market Outlook, By Therapeutics (2022-2030) ($MN)
  • Table 27 North America Anti Neurofilament L Antibody Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 28 North America Anti Neurofilament L Antibody Market Outlook, By End User (2022-2030) ($MN)
  • Table 29 North America Anti Neurofilament L Antibody Market Outlook, By Academic Institutions (2022-2030) ($MN)
  • Table 30 North America Anti Neurofilament L Antibody Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
  • Table 31 North America Anti Neurofilament L Antibody Market Outlook, By Laboratories (2022-2030) ($MN)
  • Table 32 North America Anti Neurofilament L Antibody Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 33 Europe Anti Neurofilament L Antibody Market Outlook, By Country (2022-2030) ($MN)
  • Table 34 Europe Anti Neurofilament L Antibody Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 35 Europe Anti Neurofilament L Antibody Market Outlook, By Monoclonal Antibodies (2022-2030) ($MN)
  • Table 36 Europe Anti Neurofilament L Antibody Market Outlook, By Polyclonal Antibodies (2022-2030) ($MN)
  • Table 37 Europe Anti Neurofilament L Antibody Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 38 Europe Anti Neurofilament L Antibody Market Outlook, By Application (2022-2030) ($MN)
  • Table 39 Europe Anti Neurofilament L Antibody Market Outlook, By Research (2022-2030) ($MN)
  • Table 40 Europe Anti Neurofilament L Antibody Market Outlook, By Diagnostics (2022-2030) ($MN)
  • Table 41 Europe Anti Neurofilament L Antibody Market Outlook, By Drug Discovery and Development (2022-2030) ($MN)
  • Table 42 Europe Anti Neurofilament L Antibody Market Outlook, By Therapeutics (2022-2030) ($MN)
  • Table 43 Europe Anti Neurofilament L Antibody Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 44 Europe Anti Neurofilament L Antibody Market Outlook, By End User (2022-2030) ($MN)
  • Table 45 Europe Anti Neurofilament L Antibody Market Outlook, By Academic Institutions (2022-2030) ($MN)
  • Table 46 Europe Anti Neurofilament L Antibody Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
  • Table 47 Europe Anti Neurofilament L Antibody Market Outlook, By Laboratories (2022-2030) ($MN)
  • Table 48 Europe Anti Neurofilament L Antibody Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 49 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Country (2022-2030) ($MN)
  • Table 50 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 51 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Monoclonal Antibodies (2022-2030) ($MN)
  • Table 52 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Polyclonal Antibodies (2022-2030) ($MN)
  • Table 53 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 54 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Application (2022-2030) ($MN)
  • Table 55 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Research (2022-2030) ($MN)
  • Table 56 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Diagnostics (2022-2030) ($MN)
  • Table 57 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Drug Discovery and Development (2022-2030) ($MN)
  • Table 58 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Therapeutics (2022-2030) ($MN)
  • Table 59 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 60 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By End User (2022-2030) ($MN)
  • Table 61 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Academic Institutions (2022-2030) ($MN)
  • Table 62 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
  • Table 63 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Laboratories (2022-2030) ($MN)
  • Table 64 Asia Pacific Anti Neurofilament L Antibody Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 65 South America Anti Neurofilament L Antibody Market Outlook, By Country (2022-2030) ($MN)
  • Table 66 South America Anti Neurofilament L Antibody Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 67 South America Anti Neurofilament L Antibody Market Outlook, By Monoclonal Antibodies (2022-2030) ($MN)
  • Table 68 South America Anti Neurofilament L Antibody Market Outlook, By Polyclonal Antibodies (2022-2030) ($MN)
  • Table 69 South America Anti Neurofilament L Antibody Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 70 South America Anti Neurofilament L Antibody Market Outlook, By Application (2022-2030) ($MN)
  • Table 71 South America Anti Neurofilament L Antibody Market Outlook, By Research (2022-2030) ($MN)
  • Table 72 South America Anti Neurofilament L Antibody Market Outlook, By Diagnostics (2022-2030) ($MN)
  • Table 73 South America Anti Neurofilament L Antibody Market Outlook, By Drug Discovery and Development (2022-2030) ($MN)
  • Table 74 South America Anti Neurofilament L Antibody Market Outlook, By Therapeutics (2022-2030) ($MN)
  • Table 75 South America Anti Neurofilament L Antibody Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 76 South America Anti Neurofilament L Antibody Market Outlook, By End User (2022-2030) ($MN)
  • Table 77 South America Anti Neurofilament L Antibody Market Outlook, By Academic Institutions (2022-2030) ($MN)
  • Table 78 South America Anti Neurofilament L Antibody Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
  • Table 79 South America Anti Neurofilament L Antibody Market Outlook, By Laboratories (2022-2030) ($MN)
  • Table 80 South America Anti Neurofilament L Antibody Market Outlook, By Other End Users (2022-2030) ($MN)
  • Table 81 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Country (2022-2030) ($MN)
  • Table 82 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 83 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Monoclonal Antibodies (2022-2030) ($MN)
  • Table 84 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Polyclonal Antibodies (2022-2030) ($MN)
  • Table 85 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 86 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Application (2022-2030) ($MN)
  • Table 87 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Research (2022-2030) ($MN)
  • Table 88 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Diagnostics (2022-2030) ($MN)
  • Table 89 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Drug Discovery and Development (2022-2030) ($MN)
  • Table 90 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Therapeutics (2022-2030) ($MN)
  • Table 91 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 92 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By End User (2022-2030) ($MN)
  • Table 93 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Academic Institutions (2022-2030) ($MN)
  • Table 94 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Pharmaceutical and Biotechnology Companies (2022-2030) ($MN)
  • Table 95 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Laboratories (2022-2030) ($MN)
  • Table 96 Middle East & Africa Anti Neurofilament L Antibody Market Outlook, By Other End Users (2022-2030) ($MN)